FIGURE 1.

The expression of TRIM33 in clinical samples of patients with osteoporosis and TRIM33 bound to FOXO3a. (a) The protein level of TRIM33 in the osteoblasts from bone tissues from osteoporosis patients was tested by Western blot and five people are assigned to each group. (b) The correlation analysis between TRIM33 expression in osteoblasts and the bone mineral density (BMD) of osteoporosis patients (n = 15, r²=0.8669, p<0.001). (c) The binding capacity of TRIM33 to FOXO3a was tested by IP assay in HOB and MC3 T3‐E1 cells. (d) Representative images of immunofluorescence staining displaying the cellular localization of FOXO3a and TRIM33 in HOB and MC3 T3‐E1 cells. (e) HOB and MC3 T3‐E1 cells were transfected with Lv‐siTRIM33 or Lv‐sicontrol for 24 h. The protein levels of TRIM33, nuclear and total FOXO3a, FOXO1 and FOXO4 were tested by Western blot. (f) HOB and MC3 T3‐E1 cells were transfected with Lv‐siTRIM33 or Lv‐sicontrol for 24 h and then treated with CHX for indicated times (0, 1, 2 and 4 h). The protein level of FOXO3a was tested by Western blot. *p < 0.05, **p < 0.01 vs. Lv‐sicontrol group. The experiment was repeated three times